Genomic signatures of homologous recombination defects in prostate cancer

Versión para impresiónVersión en PDF
  • Joaquín Mateo. Vall d'Hebron Instituto of Oncology (VHIO).

Proyecto asignado a través de la Red Española de Supercomputación (RES).

Precision medicine is an unmet need in metastatic prostate cancer (mPC). PARP inhibitors are now approved for the treatment of mPC associated with HRR mutations; however, significant inter-patient variability in outcome exist; better predictive biomarkers for patient stratification are needed. Genomic signatures of HRR defects have putative predictive value in other tumor types, but their clinical significance in prostate cancer is unknown. We will study the distribution of genomic events associated to HRR defects (LOH, LST, NTAI, CNA patterns) and derived signatures. We will test the hypothesise, based on data from our lab, that these signatures are enriched with resistance to hormonal treatments. We will study these features in WES and WGS datasets covering the disease spectrum, from treatment-naïve to late-stage drug resistant mPC.